https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3AGLP-1_receptor_agonist%2F3%2FenTranslations:GLP-1 receptor agonist/3/en - Revision history2026-09-08T19:49:35ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:GLP-1_receptor_agonist/3/en&diff=110953&oldid=prevFuzzyBot: Importing a new version from external source2024-02-05T12:59:56Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>GLP-1 agonists were initially developed for [[type 2 diabetes]]. The 2022 [[American Diabetes Association]] standards of medical care recommend GLP-1 agonists as a first line therapy for type 2 diabetes, specifically in patients with [[atherosclerotic cardiovascular disease]] or [[obesity]]. The drugs were also noted to reduce food intake and body weight significantly, and some have also been approved to treat obesity in the absence of diabetes. They are also in development for other indications, such as [[non-alcoholic fatty liver disease]], [[polycystic ovary syndrome]], and diseases of the [[reward system]] such as addictions.</div>FuzzyBot